1. Home
  2. NMS vs ACET Comparison

NMS vs ACET Comparison

Compare NMS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Minnesota Quality Municipal Income Fund

NMS

Nuveen Minnesota Quality Municipal Income Fund

N/A

Current Price

$9.97

Market Cap

73.2M

Sector

Finance

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$6.64

Market Cap

83.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NMS
ACET
Founded
1993
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.2M
83.3M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
NMS
ACET
Price
$9.97
$6.64
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $33.17
AVG Volume (30 Days)
41.2K
★ 243.7K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 4.11%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.48
$0.46
52 Week High
$12.50
$9.97

Technical Indicators

Market Signals
Indicator
NMS
ACET
Relative Strength Index (RSI) 33.49 38.29
Support Level N/A $6.74
Resistance Level $12.48 $7.09
Average True Range (ATR) 0.18 0.76
MACD -0.01 -0.26
Stochastic Oscillator 35.51 22.90

Price Performance

Historical Comparison
NMS
ACET

About NMS Nuveen Minnesota Quality Municipal Income Fund

Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: